



**Unaudited consolidated financial
statements of the Krka Group and
unaudited financial statements of the
Krka Company for 2013,
with important notes**

Novo mesto, February 2014

CONTENTS

Krka Group ID card.....	3
Highlights and indicators	4
Sales	5
Research and development.....	10
Investments	12
Employees.....	12
Share and investor information.....	13
Plans for 2014	13
Krka Group consolidated statement of financial position (unaudited).....	14
Krka Group consolidated income statement (unaudited).....	15
Krka Group consolidated statement of comprehensive income (unaudited)	15
Krka Group consolidated statement of changes in equity for 2013 (unaudited)	16
Krka Group consolidated statement of changes in equity for 2012 (unaudited)	17
Krka Group consolidated statement of cash flows (unaudited)	18
Krka Company statement of financial position (unaudited)	19
Krka Company income statement (unaudited)	20
Krka Company statement of comprehensive income (unaudited)	20
Krka Company statement of changes in equity for 2013 (unaudited)	21
Krka Company statement of changes in equity for 2012 (unaudited)	22
Krka Company statement of cash flows (unaudited)	23

Based on the provisions of Article 386 of the Markets in Financial Instruments Act, Krka, d. d., Šmarješka cesta 6, 8501 Novo mesto, hereby releases

IMPORTANT NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS OF THE KRKA GROUP AND TO THE UNAUDITED FINANCIAL STATEMENTS OF THE KRKA COMPANY FOR 2013

The unaudited consolidated financial statements of the Krka Group and the unaudited financial statements of the Krka Company for 2013, as well as comparative data for 2012, have been drawn up pursuant to the International Financial Reporting Standards (IFRS). Comparative data for 2012 are audited.

The Krka Company has no authorised capital and has not made a conditional share capital increase.

Krka Group ID card

Krka, d. d., Novo mesto (hereafter: Krka Company) is the controlling company in the Krka Group, which on 31 December 2013 included the following subsidiaries:

	Controlling company's ownership stake 31 Dec 2013 (%)
KRKA, d. d., Novo mesto	
TERME KRKA, d. o. o., Novo mesto	100%
Farma GRS, d. o. o., Novo mesto	99.7%
KRKA-FARMA d. o. o., Zagreb, Croatia	100%
KRKA ROMANIA S.R.L., Bucharest, Romania	100%
KRKA-FARMA DOO BEOGRAD, Belgrade, Serbia	100%
KRKA-FARMA DOOEL, Skopje, Macedonia	100%
KRKA Bulgaria EOOD, Sofia, Bulgaria	100%
KRKA FARMA d. o. o., Sarajevo, Sarajevo, Bosnia and Herzegovina	100%
KRKA-RUS LLC, Istra, Russian Federation	100%
KRKA FARMA LLC, Sergiev Posad, Russian Federation	100%
KRKA UKRAINE LLC, Kiev, Ukraine	100%
LLC »KRKA Kazakhstan«, Almati, Kazakhstan	100%
KRKA - POLSKA, Sp. z o. o., Warsaw, Poland	100%
KRKA ČR, s. r. o., Prague, Czech Republic	100%
KRKA Magyarország Kft., Budapest, Hungary	100%
KRKA Slovensko, s. r. o., Bratislava, Slovakia	100%
UAB KRKA Lietuva, Vilnius, Lithuania	100%
SIA KRKA Latvia, Riga, Latvia	100%
TAD Pharma GmbH, Cuxhaven, Germany	100%
Krka Sverige AB, Stockholm, Sweden	100%
KRKA Pharma GmbH, Vienna, Austria	100%
KRKA Farmacêutica, Unipessoal Lda., Estoril, Portugal	100%
Krka FARMACÉUTICA, S.L., Madrid, Spain	100%
KRKA FARMACEUTICI Milano S.R.L., Milan, Italy	100%
Krka France Eurl à capital variable, Paris, France	100%
KRKA PHARMA DUBLIN LIMITED, Dublin, Ireland	100%
KRKA Belgium, SA, Brussels, Belgium	95%
KRKA USA LLC, Wilmington, USA	100%

The 5% owner of the Belgium-based subsidiary is Krka France. On 31 December 2013 the subsidiary Terme Krka, d. o. o. held a 63.10% ownership stake in the company Golf Grad Otočec, d. o. o., and the subsidiary Farma GRS was the 100% owner of companies GRS Vizfarma, d. o. o. and GRS Tehfarma, d. o. o.

Highlights and indicators for the Krka Group and the Krka Company

	Krka Group		Krka Company	
EUR thousand	2013	2012	2013	2012
Revenues	1,200,827	1,143,301	1,116,339	1,035,280
EBIT ¹	227,588	192,308	211,527	161,382
EBITDA	321,732	282,276	282,993	230,994
Profit for the year	172,766	159,839	164,673	154,615
R&D costs	97,235	101,102	100,161	98,446
Investments	157,268	153,288	116,714	69,959
	31 Dec 2013	31 Dec 2012	31 Dec 2013	31 Dec 2012
Non-current assets	973,954	926,000	945,947	863,075
Current assets	785,930	700,748	755,288	702,843
Equity	1,332,612	1,240,521	1,332,246	1,232,215
Non-current liabilities	128,833	145,362	98,778	112,943
Current liabilities	298,439	240,865	270,211	220,760
RATIOS	2013	2012	2013	2012
EBIT margin	19.0%	16.8%	18.9%	15.6%
EBITDA margin	26.8%	24.7%	25.4%	22.3%
Profit margin (ROS)	14.4%	14.0%	14.8%	14.9%
ROE ²	13.4%	13.4%	12.8%	13.0%
ROA ³	10.2%	10.1%	10.1%	10.2%
Liabilities/Equity	0.321	0.311	0.277	0.271
R&D costs/Revenues	8.1%	8.8%	9.0%	9.5%
NUMBER OF EMPLOYEES	2013	2012	2013	2012
Year-end	10,048	9,461	4,628	4,495
Average	9,783	9,197	4,607	4,448

SHARE INFORMATION	2013	2012
Total number of shares issued	35,426,120	35,426,120
Earnings per share in EUR ⁴	5.24	4.80
Dividend per share in EUR	1.61	1.50
Share price at end of year in EUR ⁵	60.00	50.00
Price/Earnings ratio (P/E)	11.46	10.41
Book value in EUR ⁶	37.62	35.02
Price/Book value (P/B)	1.60	1.43
Market capitalisation in EUR thousand (31 December)	2,125,567	1,771,306

¹ Difference between operating income and expenses

² Profit for the year/Average shareholders' equity in the year

³ Profit for the year/Average total assets in the year

⁴ Profit for the year attributable to equity holders of the parent/Average number of shares issued in the year, exclusive of treasury shares


⁵ Share price on the Ljubljana Stock Exchange

⁶ Equity as at 31 December 2013/Total shares issued

Business operations analysis

Sales

The Group sold EUR 1,200.8 million worth of products and services last year, up EUR 57.5 million, or 5%, compared to 2012. The average annual sales growth rate in the past five years has been 4.8%. A more detailed analysis of the sales results is given in the chapter Sales.



Operating expenses

The Krka Group incurred EUR 979.1 million of operating expenses in 2013, an increase by EUR 19.6 million, or 2%, compared to 2012.

The Group's operating expenses included EUR 489.3 million of the cost of sales (41% of sales), EUR 323.4 million of distribution expenses (27% of sales), EUR 97.2 million of R&D costs (8% of sales), and EUR 69.2 million of administrative expenses (6% of sales). Over the last five years, the operating expenses to sales ratio has ranged from 81% in 2010 to 86% in 2009, a figure partly caused by newly formed provisions. In 2013 the operating expenses to sales ratio was 82%.



Financial income and expenses

EUR thousand	Krka Group					Krka Company				
	2013	2012	2011	2010	2009	2013	2012	2011	2010	2009
Financial income	2,114	5,418	493	7,150	885	5,316	22,431	14,046	10,637	12,160
Financial expenses	-28,361	-7,227	-12,079	-3,912	-10,206	-28,967	-7,690	-11,822	-3,637	-9,241
Net financial result	-26,247	-1,809	-11,586	3,238	-9,321	-23,651	14,741	2,224	7,000	2,919

In 2013 the Group's net financial result deteriorated compared to 2012, attributable to EUR 27.6 million of negative net exchange rate differences. In 2012 Krka had recorded EUR 4.1 million of positive exchange rate differences.

The highest item in financial income is EUR 1.5 million of interest income, while the highest item in financial expenses is in addition to negative net exchange rates EUR 0.5 million of interest expenses for non-current and current borrowings.

Operating result



The Group recorded EUR 227.6 million of operating profit, up EUR 35.3 million, or 18%, compared to 2012. Group EBITDA was EUR 321.7 million, an increase by 14%, or EUR 39.5 million.

Profit before tax increased by EUR 10.8 million, or 6%, in 2013, totalling EUR 201.3 million. The Group effective tax rate was 14.2%, down 1.9 of a percentage point compared to the year before.

The Group recorded EUR 172.8 million of profit for the period, up EUR 12.9 million, or 8%, compared to the year before.

Assets

EUR thousand	Krka Group					Krka Company				
	2013	Share (%)	2012	Share (%)	Index 13/12	2013	Share (%)	2012	Share (%)	Index 13/12
Non-current assets	973,954	55.3	926,000	56.9	105	945,947	55.6	863,075	55.1	110
Property, plant and equipment	823,704	46.8	772,291	47.5	107	563,978	33.2	519,219	33.1	109
Intangible assets	115,744	6.6	118,507	7.3	98	28,303	1.7	29,908	1.9	95
Investments and loans	11,076	0.6	10,487	0.6	106	338,372	19.9	297,183	19.0	114
Other	23,430	1.3	24,715	1.5	95	15,294	0.8	16,765	1.1	91
Current assets	785,930	44.7	700,748	43.1	112	755,288	44.4	702,843	44.9	107
Inventories	235,820	13.4	250,751	15.4	94	190,968	11.2	190,555	12.2	100
Receivables	461,828	26.2	415,233	25.6	111	441,619	26.0	432,935	27.6	102
Other	88,282	5.1	34,764	2.1	254	122,701	7.2	79,353	5.1	155
Total assets	1,759,884	100.0	1,626,748	100.0	108	1,701,235	100.0	1,565,918	100.0	109

At the year-end of 2013, Krka Group assets were worth EUR 1,759.9 million, up EUR 133.1 million, or 8%, compared to the end of 2012. Non-current assets grew primarily due to the increase in the value of property, plant and equipment, which was up EUR 51.4 million, or 7%.

Non-current assets amounted to a total of EUR 974.0 million, up 5% compared to 2012. The largest item under non-current asset was property, plant and equipment, worth EUR 823.7 million and representing 46.8% of the Group's total assets. Intangible assets represented 6.6% of total assets.

Current assets amounted to EUR 785.9 million, an increase by 12%. The largest item under current assets was receivables, which amounted to EUR 461.8 million (11% up compared to 2012), with inventories totalling EUR 235.8 million (6% down compared to 2012). Among other current assets, loans increased by EUR 9.1 million, with cash and cash equivalents up EUR 44.3 million. They mainly include short-term deposits placed by the controlling company for periods longer than 30 days, which amounted to EUR 19.0 million at the end of 2013 and are given under current loans, and deposits with maturities under 30 days, which amounted to EUR 27.5 million at the end of the year and are given under cash and cash equivalents.

Equity and liabilities

EUR thousand	Krka Group					Krka Company				
	2013	Share (%)	2012	Share (%)	Index 13/12	2013	Share (%)	2012	Share (%)	Index 13/12
Equity	1,332,612	75.7	1,240,521	76.3	107	1,332,246	78.3	1,232,215	78.7	108
Non-current liabilities	128,833	7.3	145,362	8.9	89	98,778	5.8	112,943	7.2	87
Current liabilities	298,439	17.0	240,865	14.8	124	270,211	15.9	220,760	14.1	122
Total equity and liabilities	1,759,884	100.0	1,626,748	100.0	108	1,701,235	100.0	1,565,918	100.0	109

The Group's equity increased by EUR 92.1 million compared to the end of 2012. The increase is mostly attributable to Group profit for the year, totalling EUR 172.8 million, while the decrease is mainly caused by EUR 53.1 million of dividend payments, by EUR 13.7 million of additional repurchases of treasury shares and by EUR 13.5 million of translation reserves.

At the end of 2013 the Krka Group had no borrowings. Provisions totalled EUR 103.1 million, a decrease by 2% compared to the end of 2012, attributable mainly to outflows and reversals of the provisions for retirement benefits and anniversary bonuses, while the provisions for lawsuits remained on EUR 49.1 million EUR which is level from the end of 2012

Current liabilities at the end of 2013 amounted to 298.4 million EUR, up 24% compared to 2012. Liabilities include also EUR 2 million accrued in relation to the decision of the Appeal Court from Oslo, which has ruled that the subsidiary Krka Sverige shall compensate the company Astra Zeneca for lost profit and legal expenses due to the alleged infringement of the patent right protecting the medicineesomeprazole.

Statement of cash flows


EUR thousand	Krka Group		Krka Company	
	2013	2012	2013	2012
Net cash from operating activities	302,751	278,329	251,954	207,216
Net cash used in investing activities	-164,065	-166,910	-146,522	-129,913
Net cash used in financing activities	-93,683	-108,012	-68,821	-78,578
Net increase/decrease in cash and cash equivalents	45,003	3,407	36,611	-1,275

Krka Group cash and cash equivalents increased by EUR 45.0 million in 2013, due to the positive cash flow from operating activities exceeding the negative cash flows from investing and financing activities.

The Group reported EUR 294.7 million of operating profit before changes in net operating current assets. The changes in current assets that increased profit were changes in inventories, trade payables, provisions, deferred revenue and other current liabilities, while trade receivables had a negative effect.

The negative cash flow from investing activities was mainly the result of the purchase of property, plant and equipment, amounting to EUR 151.7 million, the purchase of intangible assets, amounting to EUR 5.6 million, and the payments in connection with current investments and loans, amounting to EUR 8.8 million. The main causes of the negative cash flow from financing activities were dividend payments, which totalled EUR 53.0 million, repayments of non-current borrowings, which totalled EUR 25.5 million, and the repurchase of treasury shares, which totalled EUR 13.7 million.

Performance ratios



Performance ratio values were in compliance with strategic guidelines.

Operating figures for the Krka Group and the Krka Company for the last five years

EUR thousand	Krka Group					Krka Company				
	2013	2012	2011	2010	2009	2013	2012	2011	2010	2009
Revenues	1,200,827	1,143,301	1,075,627	1,010,021	953,038	1,116,339	1,035,280	957,653	932,366	850,119
EBIT	227,588	192,308	211,561	208,134	233,643	211,527	161,382	178,150	196,397	210,737
– EBIT margin	19.0%	16.8%	19.7%	20.6%	24.5%	18.9%	15.6%	18.6%	21.1%	24.8%
EBITDA	321,732	282,276	298,747	289,855	310,318	282,993	230,994	244,564	257,132	269,532
– EBITDA margin	26.8%	24.7%	27.8%	28.7%	32.6%	25.4%	22.3%	25.5%	27.6%	31.7%
Profit for the year	172,766	159,839	162,735	170,918	173,685	164,673	154,615	150,392	165,920	170,812
– Profit margin	14.4%	14.0%	15.1%	16.9%	18.2%	14.8%	14.9%	15.7%	17.8%	20.1%
Assets	1,759,884	1,626,748	1,534,027	1,488,204	1,341,032	1,701,235	1,565,918	1,463,062	1,445,869	1,312,413
ROA	10.2%	10.1%	10.8%	12.1%	13.3%	10.1%	10.2%	10.3%	12.0%	13.5%
Equity	1,332,612	1,240,521	1,139,754	1,053,327	920,369	1,332,246	1,232,215	1,140,485	1,058,154	932,010
ROE	13.4%	13.4%	14.8%	17.3%	20.4%	12.8%	13.0%	13.7%	16.7%	19.8%

Sales

Krka Group sales by Region

	Krka Group			Krka Company		
EUR thousand	2013	2012	Index	2013	2012	Index
Slovenia	86,596	91,002	95	57,476	60,086	96
South-East Europe	145,808	148,140	98	164,139	152,568	108
East Europe	427,803	354,213	121	388,885	295,612	132
Central Europe	282,940	282,400	100	279,649	287,162	97
West Europe and Overseas Markets	257,680	267,546	96	226,190	239,852	94
Total	1,200,827	1,143,301	105	1,116,339	1,035,280	108

In 2013 the Krka Group sold EUR 1,200.8 million worth of products and services, of which EUR 1,114.2 million, almost 93% of the total, came from markets outside Slovenia. Sales growth was recorded in Krka's sales region East Europe (up 21%), while sales in Region Central Europe remained on the level recorded in 2012. Sales were down in regions Slovenia, South-East Europe, and West Europe and Overseas Markets, where they declined by 5%, 2% and 4%, respectively.

Krka's leading sales region was Region East Europe, which contributed 35.6%, or EUR 427.8 million, of overall sales and where double-digit sales growth rates were recorded in the majority of markets. In the Russian Federation, one of Krka's key markets as well as our largest single market, we sold EUR 298.0 million worth of products, a 22% increase from 2012. Other large markets in the Region that recorded double-digit sales growth were Ukraine (up 11%), Kazakhstan (up 31%), Uzbekistan (up 21%) and Belarus (up 31%).

Krka's second most important region in terms of sales was Region Central Europe, where we generated EUR 282.9 million, which is 23.6% of overall sales. In Poland, the Region's largest market and one of Krka's key markets, product sales amounted to EUR 121.5 million, up 9% from 2012, while in the Czech Republic, the second largest market in the Region, product sales were EUR 63.0 million, down 6%. The decrease is chiefly attributable to legislative changes which had a negative impact on the prices of pharmaceuticals. Key market Hungary is the third most important market in the Region in terms of sales volume. Sales continued to decrease there in 2013, when they amounted to EUR 42.7 million, down 12% compared to the year before. Sales growth was also recorded in Slovakia (up 3%), Latvia (up 12%) and Estonia (up 1%), while in Lithuania sales were down 6%.

Region West Europe and Overseas Markets was third in terms of sales value last year, contributing EUR 257.7 million, which is 21.5% of total Krka Group sales. The decline was due to the lower sales of prescription pharmaceuticals via partners, which, however, was partly offset by the higher sales via subsidiaries; their share of overall sales in the Region has increased to 41%. With EUR 53.2 million of sales generated in Germany, this country remains the Region's largest market.

In Region South-East Europe Krka sold EUR 145.8 million of products, which represents 12.1% of Group sales. The Region's largest market is Romania, where sales in 2013 amounted to EUR 50.6 million, followed by Croatia, where Krka sold EUR 32.5 million worth of products. Sales value increased in Romania, Macedonia and Kosovo, while in the Region's other markets sales were down.

Product and service sales in Slovenia amounted to EUR 86.6 million, which is 7.2% of Group sales. Our operations in the domestic market of prescription pharmaceuticals were largely influenced by austerity measures and the related gradually escalating pressure to reduce the prices of our pharmaceuticals. Because of that value of sales of prescription pharmaceuticals didn't reach the value from 2012 although Krka maintained the highest market share (11.6%).

Krka Group sales by product and service group

EUR thousand	Krka Group			Krka Company		
	2013	2012	Index	2013	2012	Index
Human health products	1,126,161	1,067,573	105	1,070,561	990,645	108
– Prescription pharmaceuticals	980,903	944,578	104	943,981	889,595	106
– Non-prescription products	145,258	122,995	118	126,580	101,050	125
Animal health products	42,592	42,752	100	42,824	42,574	101
Health resort and tourist services	30,466	31,864	96			
Other	1,608	1,112	145	2,954	2,061	143
Total	1,200,827	1,143,301	105	1,116,339	1,035,280	108

Krka's most important group of products in terms of sales remain prescription pharmaceuticals, which contributed EUR 980.9 million of overall sales, up 4% from 2012. The best-selling therapeutic group of prescription pharmaceuticals in 2013 were again products treating cardiovascular diseases, followed by medicines treating gastrointestinal and metabolic disorders, and by medicines for diseases of the central nervous system.

Krka's 10 leading prescription pharmaceuticals in terms of sales value in 2013 were Atoris (atorvastatin), Lorista/Lavestra (losartan), Enap (enalapril), Prenessa/Perineva (perindopril), Nolpaza/Nolpaza control/Appryo (pantoprazole), Zyllt/Kardogrel (clopidogrel), Emozul/Emanera/Escadra (esomeprazole), Valsacor (valsartan), Roswera/Roxera/Sorvasta (rosuvastatin) and Karbis/Candecor/Canocord (candesartan).

Non-prescription product sales amounted to EUR 145.3 million, up 18% year-on-year, while animal health product sales remained on the level from 2012, amounting to EUR 42.6 million. Health resort and tourist services generated EUR 30.5 million of sales, a decrease by 4% compared to the year before. Other Group sales revenues amounted to EUR 1.6 million.

Research and development

In 2013 Krka obtained marketing authorisations for 17 new products (13 prescription pharmaceuticals, three non-prescription products and one animal health product) in 35 different dosage forms and strengths. Numerous products were authorised under different European and national marketing authorisation procedures, resulting in 515 new approvals for our products in different countries.

In 2013 Krka submitted patent applications for ten inventions and two international patent applications on the basis of prioritised applications from 2012. We registered 45 trademarks in Slovenia, and submitted 38 international and 32 national trademark applications.

We were the first pharmaceutical company in Europe to obtain a marketing authorisation for the fixed-dose combination of three active substances **Co-Amlessa/Co-Dalnessa** (perindopril, indapamide and amlodipine) in the form of tablets in three strengths. The product is used to control high blood pressure, and enables the simultaneous use of all three medications with complementary mechanisms of action. The simple once-a-day administration increases patient cooperation and improves the desired efficiency of blood pressure control.

Further in our range of products used to lower blood pressure, we obtained approvals in all European countries for the new product **Tolucombi** (fixed-dose combination of telmisartan and hydrochlorothiazide) in the form of tablets, indicated in patients whose blood pressure is not adequately controlled on one product alone. This has successfully completed the development of Krka's first medicine in the form of bilayer tablets, which enable the incorporation of several active substances into one tablet, even with substances that are not well compatible on account of their physical and chemical properties and mutual interactions. The innovation won Krka the Gold Innovation Award bestowed by the Chamber of Commerce and Industry of Slovenia.

We also obtained approvals for **Opryme** (pramipexole) prolonged-release tablets in five strengths, used either in mono- or combination therapy to treat the signs and symptoms of Parkinson's disease. It can be taken once a day.

Approvals were obtained for the new medicine **Amaloris** (fixed-dose combination of atorvastatin and amlodipine) in the form of film-coated tablets, thereby supplementing Krka's range of products for the treatment of cardiovascular diseases. The fixed-dose combination of the two substances from different indication areas allows for a holistic treatment of patients with cardiovascular conditions and efficiently reduces cardiovascular risks.

As the first generic company we obtained marketing authorisations in 15 European countries for **Elernap** (fixed-dose combination of enalapril and lercanidipine) tablets in two strengths. The product is indicated in the treatment of essential hypertension in cases when monotherapy with lercanidipine proves insufficient and does not give the adequate results for high blood pressure.

We also obtained approvals for **Sobycor** (bisoprolol) tablets in three strengths. This adrenoceptor antagonist with once-daily dosing efficiently reduces blood pressure in patients with mild to moderate hypertension, and improves cardiac performance in patients with angina pectoris.

In Europe we acquired marketing authorisations for memantine film-coated tablets in two strengths, used to treat patients with mild to moderate Alzheimer's disease. Having obtained approvals for memantine, Krka has supplemented its range of medicines to treat Alzheimer's disease to now include all active substances used in clinical practice.

Also in Europe we obtained approvals to market the new product **Aclexa** (celecoxib), consolidating our range of nonsteroidal anti-inflammatory products. In the form of hard shell capsules in two strengths this pain reliever and inflammation reducer is indicated in various rheumatic diseases, including rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

Krka's range of products for the treatment of the central nervous system was supplemented with the antidepressant **Elicea Q-Tab** (escitalopram) in the new form of orodispersible tablets in four strengths. The new form dissolves rapidly in the mouth and can be taken without water, making it especially appropriate for patients that have difficulty swallowing a tablet.

In the Russian Federation we obtained marketing authorisations for the new medicine **Naklofen Protect dual pack**, which contains capsules with 75 mg of diclofenac and 15 mg of lansoprazole in the same pack. It is used to relieve pain and treat all forms of rheumatic diseases that require long-term treatment with diclofenac. The simultaneous use of lansoprazole decreases the chance of bleeding, ulceration and perforations of the intestinal mucosa, which are frequent adverse effects caused by diclofenac, especially during its long-term use as well as in older patients and in patients with intestinal hypersensitivity and gastric erosions.

We completed marketing authorisation procedures for our first group of neoplasm medications. Applying the decentralised procedure we obtained approvals for **Meaxin** (imatinib) film-coated tablets and for the **Tolnexa** (docetaxel) concentrate for solution for infusion. Meaxin is used to treat chronic myeloid leukaemia, and Tolnexa is used either separately or in combination therapy to treat breast cancer, locally advanced or non-small cell metastatic lung cancer, metastatic prostate cancer, metastatic stomach cancer, and locally advanced head and neck cancer. In the Russian Federation we obtained approvals under the national procedure for **Balutar** (bicalutamide) film-coated tablets in two strengths, used to treat prostate cancer.

Marketing authorisations were granted under the decentralised procedure in seven European countries for **Nalgesin 220 mg** (naproxen) film-coated tablets in the new strength of 220 mg. The product supplements Krka's range of pain relievers with a dosage permitted without a prescription in most markets and intended for self-medication.

As to cold remedies, we were granted approvals for **Septanazal nasal spray for adults** and **Septanazal nasal spray for children** (xylometazoline). Both products combine a local decongestant, which reduces the swelling of the nasal mucosa and nasal secretions, and dexpanthenol, which moisturises and heals the damaged nasal mucosa. The two products are intended to relieve breathing problems with nasal congestion during colds.

In 2013 we obtained the first notification for our new veterinary hygiene biocidal product **Ecocid Advanced** in the form of water-soluble powder. The first notification was granted in Slovenia, while additional notifications were subsequently also obtained in Lithuania, Slovakia and the Czech Republic, with a marketing authorisation being

granted for the product in the Russian Federation. It is an all-purpose highly active disinfectant intended for the disinfection of surfaces and equipment in veterinary health and contemporary animal breeding. The release of peracetic acid decontaminates from viruses, bacteria and their spores, as well as from yeasts and moulds.

Investments

In 2013 the Krka Group allocated EUR 157.3 million to investments, of which the controlling company invested EUR 116.7 million and subsidiaries EUR 40.6 million. Investments were primarily increasing and modernising our production, and research and development infrastructure.

In June 2012 construction works started at Krka's central location at Ločna in Novo mesto, Slovenia for the Notal 2 production plant for solid dosage pharmaceuticals. The estimated investment value of the largest investment in Krka's history is EUR 200 million. Production in the 55,000 m plant will start by the end of 2015.

In July 2012 we had begun constructing a new active pharmaceutical ingredients production complex in Krško, Slovenia. In the first stage we are building the Sinteza 1 production plant and the related infrastructure. The project's estimated investment value is EUR 85 million, and production will start by the end of 2014.

At Krka's central location we are also constructing a new water preparation plant to ensure sufficient capacity for the preparation of purified waters and tower feedwater, and to provide for a secure supply after Notal 2 is constructed. The investment is worth an estimated EUR 13.7 million. We obtained the building permit at the beginning of October 2013, and the facility is planned to be completed by the end of 2014.

The simultaneous generation of heat and power (cogeneration) increases the recovery of energy conversion and enables an efficient use of primary energy. At Ločna in Novo mesto, Slovenia, we have set up a natural-gas-powered engine cogeneration system, increasing the economic efficiency of our generation of electricity and utilisation of heat energy. The project's investment value was EUR 1.7 million.

One of the Group's more important ongoing investments is the Krka-Rus 2 project, the construction of a new plant and expansion of our logistics centre in the Russian Federation. The plant with the target production capacity of 1.8 billion tablets and capsules per year and a total surface area of 36,000 m², is consolidating Krka's status as a domestic pharmaceuticals producer in this country. The project's estimated investment value is EUR 135 million, with the first stage, which was completed in 2013, worth EUR 95 million. The new logistics centre with the high-bay warehouse entered into use in July 2013, the packaging of finished products began in October, while in December all formal conditions were also met to launch the production of bulk products.

The health spa resort subsidiary Terme Krka opened the Otočec adventure park in April 2013, constructed a new geothermal well in its Dolenjske Toplice resort, and renovated and expanded the restaurant of the Šmarješke Toplice resort.

The investment into Krka's subsidiary Farma GRS, d. o. o., a company which we founded together with partners in a project aimed at advancing the pharmaceuticals industry, is in its final stage. At our location in Ločna, Novo mesto, Slovenia we are setting up new research and development, and production facilities. The project's investment value is EUR 45 million, and it is being co-funded by the European Union, contributing over EUR 10 million from the European Regional Development Fund.

Employees

At the end of 2013 the Krka Group had 10,048 employees, of which 4,846 (48.2%) worked in Slovenia and 5,202 (51.8%) abroad.

Compared to the figures for 2012, the number of employees at Group level increased by 587, or 6%. The number of Krka employees working outside Slovenia increased by 505, or 11%, and the number of those in Slovenia rose by 82, or 2%.

Krka Group staff with a university level education or higher currently represent as many as 53% of the entire team, which is 5,361 employees; 111 of them have a doctoral degree and 323 have master's degrees or postgraduate specialisations.

Share and investor information

On the final trading day in 2013 Krka's share traded at EUR 60.00 on the Ljubljana Stock Exchange, up 20% on the year-end of 2012 when it traded at EUR 50.00. In the same period the Slovene blue-chip index SBI TOP rose by 3%. Krka's market capitalisation totalled EUR 2.1 billion at the end of last year.

The average daily trading volume in Krka's share on the Ljubljana Stock Exchange in 2013 was EUR 0.5 million, preserving Krka's position as the most actively traded security on the Ljubljana Stock Exchange.

At the end of 2013 Krka had 64,136 shareholders, 6% less than at the end of 2012 when there were 68,026. The shareholdings of international investors increased the most, reaching a total of slightly over 20% of all issued shares. Slovenian shareholders, i.e. investment funds and companies, and other companies and individuals, decreased their shareholdings.

In 2013 Krka appropriated 33% of the 2012 profit for dividends, gross dividend per share exceeding 7%. At the end of the year the company adopted a new Krka Group development strategy for the period 2014–2018, stipulating, among other things, a new dividend policy. It states that in the period 2014–2018, up to 50% of the Group's profit for the previous year attributable to equity holders of the parent, will now be allocated to dividends, whereby the actual amount of profit allocated to dividends each year will also depend on Krka's financial requirements related to investments and major acquisitions.

Since April 2012 Krka's shares have also been listed on the Warsaw Stock Exchange.

Plans for 2014

Krka Group sales are planned to amount to EUR 1.245 billion in 2014, with profit for the year expected at the level of the profit reported for 2013. Our largest sales region will be East Europe

The estimated value of investments is EUR 164 million, to be allocated mainly to expanding and modernising production facilities, research and development facilities, and infrastructure. The number of employees is planned to increase in 2014 both in Slovenia and abroad, by slightly more than 4% altogether.

Novo mesto, February 2014

Krka, d. d., Novo mesto
Management Board

Krka Group consolidated statement of financial position (unaudited)

EUR thousand	31 Dec 2013	31 Dec 2012
Assets		
Property, plant and equipment	823,704	772,291
Intangible assets	115,744	118,507
Non-current loans	5,845	5,387
Non-current investments	5,231	5,100
Deferred tax assets	23,236	24,512
Other non-current assets	194	203
Total non-current assets	973,954	926,000
Inventories	235,820	250,751
Trade receivables	430,435	372,305
Other receivables	31,393	42,928
Current loans	20,215	11,091
Current investments	792	679
Cash and cash equivalents	67,275	22,994
Total current assets	785,930	700,748
Total assets	1,759,884	1,626,748
Equity		
Share capital	59,126	59,126
Treasury shares	-69,371	-55,656
Reserves	194,458	192,069
Retained earnings	1,147,031	1,043,544
Equity holders of the parent	1,331,244	1,239,083
Non-controlling interest	1,368	1,438
Total equity	1,332,612	1,240,521
Liabilities		
Non-current borrowings	0	12,900
Provisions	103,103	104,746
Deferred revenue	12,805	12,424
Deferred tax liabilities	12,925	15,292
Total non-current liabilities	128,833	145,362
Trade payables	131,227	105,415
Current borrowings	0	13,355
Income tax liabilities	7,030	2,497
Other current liabilities	160,182	119,598
Total current liabilities	298,439	240,865
Total liabilities	427,272	386,227
Total equity and liabilities	1,759,884	1,626,748

Krka Group consolidated income statement (unaudited)

EUR thousand	2013	2012
Revenues	1,200,827	1,143,301
Cost of sales	-489,266	-467,557
Gross profit	711,561	675,744
Other income	5,868	8,526
Distribution expenses	-323,361	-318,215
R&D costs	-97,235	-101,102
Administrative expenses	-69,245	-72,645
Operating profit	227,588	192,308
Financial income	2,114	5,418
Financial expenses	-28,361	-7,227
Net financial expenses	-26,247	-1,809
Profit before tax	201,341	190,499
Income tax expense	-28,575	-30,660
Profit for the year	172,766	159,839
Attributable to:		
– equity holders of the parent	172,836	159,915
– non-controlling interest	-70	-76
Basic earnings per share (in EUR)	5.24	4.80
Diluted earnings per share (in EUR)	5.24	4.80

Krka Group consolidated statement of comprehensive income (unaudited)

EUR thousand	2013	2012
Profit for the year	172,766	159,839
Other comprehensive income for the year		
Changes in profits of previous periods	-2,494	0
Change in fair value of available-for-sale financial assets	131	106
Deferred tax effect – change in fair value of available-for-sale financial assets	-2	19
Actuarial surplus/deficit	2,514	-910
Deferred tax effect – impact of actuarial calculation	-427	260
Translation reserve	-13,542	4,463
Total other comprehensive income for the year	-13,820	3,938
Total comprehensive income for the year	158,946	163,777
Attributable to:		
– equity holders of the parent	159,016	163,853
– non-controlling interest	-70	-76

Krka Group consolidated statement of changes in equity for 2013 (unaudited)

EUR thousand	Reserves								Retained earnings			Total equity of the parent	Non-controlling interest	Total equity
	Share capital	Treasury shares	Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Translation reserve	Other revenue reserves	Profit for the year	Retained earnings			
Balance at 1 Jan 2013	59,126	-55,656	55,656	101,503	14,990	30,000	1,667	-11,747	846,998	121,843	74,703	1,239,083	1,438	1,240,521
Profit for the year	0	0	0	0	0	0	0	0	0	172,836	0	172,836	-70	172,766
Other comprehensive income for the year														
Changes in profits of previous periods	0	0	0	0	0	0	0	0	0	-1	-2,493	-2,494	0	-2,494
Change in fair value of available-for-sale financial assets	0	0	0	0	0	0	131	0	0	0	0	131	0	131
Deferred tax effect – change in fair value of available-for-sale financial assets	0	0	0	0	0	0	-2	0	0	0	0	-2	0	-2
Actuarial surplus/	0	0	0	0	0	0	2,514	0	0	0	0	0	0	2,514
Deferred tax effect – impact of actuarial calculation	0	0	0	0	0	0	-427	0	0	0	0	-427	0	-427
Translation reserve	0	0	0	0	0	0	0	-13,542	0	0	0	-13,542	0	-13,542
Total other comprehensive income for the year	0	0	0	0	0	0	2,216	-13,542	0	-1	-2,493	-13,820	0	-13,820
Total comprehensive income for the year	0	0	0	0	0	0	2,216	-13,542	0	172,835	-2,493	159,016	-70	158,946
Transactions with owners, recognised directly in equity														
Formation of legal reserves	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Formation of statutory reserves	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Formation of other revenue reserves under the resolution of the Management and Supervisory Boards	0	0	0	0	0	0	0	0	34,000	-34,000	0	0	0	0
Transfer of previous period's profit to retained earnings	0	0	0	0	0	0	0	0	0	-121,843	121,843	0	0	0
Transfer to other revenue reserves under the resolution of the Annual General Meeting	0	0	0	0	0	0	0	0	62,395	0	-62,395	0	0	0
Formation of reserves for treasury shares	0	0	13,715	0	0	0	0	0	0	-13,715	0	0	0	0
Repurchase of treasury shares	0	-13,715	0	0	0	0	0	0	0	0	0	-13,715	0	-13,715
Dividends paid	0	0	0	0	0	0	0	0	0	0	-53,140	-53,140	0	-53,140
Acquisitions of non-controlling interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total transactions with owners, recognised directly in equity	0	-13,715	13,715	0	0	0	0	0	96,395	-164,258	6,308	-66,855	0	-66,855
Balance at 31 Dec 2013	59,126	-69,371	69,371	101,503	14,990	30,000	3,883	-25,289	943,393	116,958	78,518	1,331,244	1,368	1,332,612

Krka Group consolidated statement of changes in equity for 2012 (unaudited)

EUR thousand	Reserves								Retained earnings			Equity holders of the parent	Non-controlling interest	Total equity
	Share capital	Treasury shares	Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserve	Translation reserve	Other revenue reserves	Profit for the year	Retained earnings			
Balance at 1 Jan 2012	59,126	-42,584	42,584	101,503	14,990	30,000	1,542	-16,210	760,611	124,150	62,528	1,138,240	1,514	1,139,754
Profit for the year	0	0	0	0	0	0	0	0	0	159,915	0	159,915	-76	159,839
Other comprehensive income for the year														
Actuarial deficit	0	0	0	0	0	0	0	0	0	0	-910	-910	0	-910
Change in fair value of available-for-sale financial assets	0	0	0	0	0	0	106	0	0	0	0	106	0	106
Deferred tax effect – change in fair value of available-for-sale financial assets	0	0	0	0	0	0	19	0	0	0	0	19	0	19
Deferred tax effect – impact of actuarial calculation	0	0	0	0	0	0	0	0	0	0	260	260	0	260
Translation reserve	0	0	0	0	0	0	0	4,463	0	0	0	4,463	0	4,463
Total other comprehensive income for the year	0	0	0	0	0	0	125	4,463	0	0	-650	3,938	0	3,938
Total comprehensive income for the year	0	0	0	0	0	0	125	4,463	0	159,915	-650	163,853	-76	163,777
Transactions with owners, recognised directly in equity			0											
Formation of statutory reserves	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Formation of other revenue reserves under the resolution of the Management and Supervisory Boards	0	0	0	0	0	0	0	0	25,000	-25,000	0	0	0	0
Transfer of previous period's profit to retained earnings	0	0	0	0	0	0	0	0	0	-124,150	124,150	0	0	0
Transfer to other revenue reserves under the resolution of the Annual General Meeting	0	0	0	0	0	0	0	0	61,387	0	-61,387	0	0	0
Formation of reserves for treasury shares	0	0	13,072	0	0	0	0	0	0	-13,072	0	0	0	0
Repurchase of treasury shares	0	-13,072	0	0	0	0	0	0	0	0	0	-13,072	0	-13,072
Dividends paid	0	0	0	0	0	0	0	0	0	0	-49,938	-49,938	0	-49,938
Acquisitions of non-controlling interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total transactions with owners, recognised directly in equity	0	-13,072	13,072	0	0	0	0	0	86,387	-162,222	12,825	-63,010	0	-63,010
Balance at 31 Dec 2012	59,126	-55,656	55,656	101,503	14,990	30,000	1,667	-11,747	846,998	121,843	74,703	1,239,083	1,438	1,240,521

Krka Group consolidated statement of cash flows (unaudited)

EUR thousand	2013	2012
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit for the period	172,766	159,839
Adjustments for:	121,983	129,360
– amortisation/depreciation	94,144	89,968
– foreign exchange differences	-770	2,242
– investment income	-2,253	-1,894
– investment expense	2,063	6,146
– interest expense and other financial expense	718	2,238
– financial income	-494	0
– income tax	28,575	30,660
Operating profit before changes in net operating current assets	294,749	289,199
Change in trade receivables	-54,132	-18,189
Change in inventories	14,931	3,478
Change in trade payables	25,812	14,527
Change in provisions	871	-983
Change in deferred revenue	381	5,754
Change in other current liabilities	40,938	16,538
Income taxes paid	-20,799	-31,995
Net cash from operating activities	302,751	278,329
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	1,628	1,129
Dividends received	24	17
Proceeds from sale of property, plant and equipment	868	767
Purchase of intangible assets	-5,592	-8,155
Purchase of property, plant and equipment	-151,676	-145,132
Non-current loans	-1,818	-1,673
Proceeds from repayment of non-current loans	1,281	904
Acquisition of non-current investments	-50	-134
Proceeds from sale of non-current investments	59	47
Payments/Proceeds in connection with current investments and loans	-8,789	-9,795
Payments in connection with derivative financial instruments	0	-4,987
Proceeds from derivative financial instruments	0	102
Net cash used in investing activities	-164,065	-166,910
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-1,098	-2,860
Repayment of non-current borrowings	-25,500	-41,300
Payments/Proceeds in connection with current borrowings	-375	-1,010
Dividends paid	-52,995	-49,770
Repurchase of treasury shares	-13,715	-13,072
Net cash used in financing activities	-93,683	-108,012
Net increase in cash and cash equivalents	45,003	3,407
Cash and cash equivalents at beginning of year	22,994	20,187
Effect of exchange rate fluctuations on cash held	-722	-600
Net cash and cash equivalents at end of period	67,275	22,994

Krka Company statement of financial position (unaudited)

EUR thousand	31 Dec 2013	31 Dec 2012
Assets		
Property, plant and equipment	563,978	519,219
Intangible assets	28,303	29,908
Investments in subsidiaries	288,323	259,455
Non-current receivables due from subsidiaries	14,018	0
Non-current loans	31,009	32,837
Non-current investments	5,022	4,891
Deferred tax assets	15,167	16,620
Other non-current assets	127	145
Total non-current assets	945,947	863,075
Inventories	190,968	190,555
Trade receivables	426,195	412,856
Other receivables	15,424	20,079
Current loans	72,492	65,305
Current investments	792	679
Cash and cash equivalents	49,417	13,369
Total current assets	755,288	702,843
Total assets	1,701,235	1,565,918
Equity		
Share capital	59,126	59,126
Treasury shares	-69,371	-55,656
Reserves	219,744	203,816
Retained earnings	1,122,747	1,024,929
Total equity	1,332,246	1,232,215
Liabilities		
Non-current borrowings	2,000	13,700
Provisions	94,464	96,491
Deferred revenue	2,314	2,752
Total non-current liabilities	98,778	112,943
Trade payables	145,921	118,496
Current borrowings	70,190	58,917
Income tax liabilities	4,823	0
Other current liabilities	49,277	43,347
Total current liabilities	270,211	220,760
Total liabilities	368,989	333,703
Total equity and liabilities	1,701,235	1,565,918

Krka Company income statement (unaudited)

EUR thousand	2013	2012
Revenues	1,116,339	1,035,280
Cost of sales	-457,925	-433,531
Gross profit	658,414	601,749
Other income	3,007	2,316
Distribution expenses	-295,791	-288,695
R&D costs	-100,161	-98,446
Administrative expenses	-53,942	-55,542
Operating profit	211,527	161,382
Financial income	5,316	22,431
Financial expenses	-28,967	-7,690
Net financial expenses/income	-23,651	14,741
Profit before tax	187,876	176,123
Income tax expense	-23,203	-21,508
Profit for the year	164,673	154,615
Basic earnings per share (in EUR)	4.99	4.65
Diluted earnings per share (in EUR)	4.99	4.65

Krka Company statement of comprehensive income (unaudited)

EUR thousand	2013	2012
Profit for the year	164,673	154,615
Other comprehensive income for the year		
Change in fair value of available-for-sale financial assets	131	106
Deferred tax effect – change in fair value of available-for-sale financial assets	-2	19
Actuarial surplus/deficit	2,511	0
Deferred tax effect – impact of actuarial calculation	-427	0
Total other comprehensive income for the year	2,213	125
Total comprehensive income for the year	166,886	154,740

Krka Company statement of changes in equity for 2013 (unaudited)

EUR thousand	Share capital	Treasury shares	Reserves					Retained earnings			Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserves	Other revenue reserves	Profit for the year	Retained earnings	
Balance at 1 Jan 2013	59,126	-55,656	55,656	101,503	14,990	30,000	1,667	846,998	116,543	61,388	1,232,215
Profit for the year	0	0		0	0	0	0	0	164,673	0	164,673
Other comprehensive income for the year											0
Change in fair value of available-for-sale financial assets	0	0	0	0	0	0	131	0	0	0	131
Deferred tax effect – change in fair value of available-for-sale financial assets	0	0	0	0	0	0	-2	0	0	0	-2
Actuarial surplus	0	0		0	0	0	2,511	0	0	0	2,511
Deferred tax effect – impact of actuarial calculation	0	0		0	0	0	-427	0	0	0	-427
Total other comprehensive income for the year	0	0	0	0	0	0	2,213	0	0	0	2,213
Total comprehensive income for the year	0	0	0	0	0	0	2,213	0	164,673	0	166,886
Transactions with owners, recognised directly in equity											0
Formation of statutory reserves	0	0	0	0	0		0	0	0	0	0
Formation of other revenue reserves under the resolution of the Management and Supervisory Boards	0	0	0	0	0	0	0	34,000	-34,000	0	0
Transfer of previous period's profit to retained earnings	0	0	0	0	0	0	0	0	-116,543	116,543	0
Transfer to other revenue reserves under the resolution of the Annual General Meeting	0	0		0	0	0	0	62,395	0	-62,395	0
Formation of reserves for treasury shares	0	0	13,715	0	0	0	0	0	-13,715	0	0
Repurchase of treasury shares	0	-13,715	0	0	0	0	0	0	0	0	-13,715
Dividends paid	0	0	0	0	0	0	0	0	0	-53,140	-53,140
Total transactions with owners, recognised directly in equity	0	-13,715	13,715	0	0	0	0	96,395	-164,258	1,008	-66,855
Balance at 31 Dec 2013	59,126	-69,371	69,371	101,503	14,990	30,000	3,880	943,393	116,958	62,396	1,332,246

Krka Company statement of changes in equity for 2012 (unaudited)

EUR thousand	Share capital	Treasury shares	Reserves					Retained earnings			Total equity
			Reserves for treasury shares	Share premium	Legal reserves	Statutory reserves	Fair value reserves	Other revenue reserves	Profit for the year	Retained earnings	
Balance at 1 Jan 2012	59,126	-42,584	42,584	101,503	14,990	30,000	1,542	760,611	111,741	60,972	1,140,485
Profit for the year	0	0	0	0	0	0	0	0	154,615	0	154,615
Other comprehensive income for the year			0								
Change in fair value of available-for-sale financial assets	0	0	0	0	0	0	106	0	0	0	106
Deferred tax effect – change in fair value of available-for-sale financial assets	0	0	0	0	0	0	19	0	0	0	19
Total other comprehensive income for the year	0	0	0	0	0	0	125	0	0	0	125
Total comprehensive income for the year	0	0	0	0	0	0	125	0	154,615	0	154,740
Transactions with owners, recognised directly in equity											
Formation of statutory reserves	0	0	0	0	0	0	0	0	0	0	0
Formation of other revenue reserves under the resolution of the Management and Supervisory Boards	0	0	0	0	0	0	0	25,000	-25,000	0	0
Transfer of previous period's profit to retained earnings	0	0	0	0	0	0	0	0	-111,741	111,741	0
Transfer to other revenue reserves under the resolution of the Annual General Meeting	0	0	0	0	0	0	0	61,387	0	-61,387	0
Formation of reserves for treasury shares	0	0	13,072	0	0	0	0	0	-13,072	0	0
Repurchase of treasury shares	0	-13,072	0	0	0	0	0	0	0	0	-13,072
Dividends paid	0	0	0	0	0	0	0	0	0	-49,938	-49,938
Total transactions with owners, recognised directly in equity	0	-13,072	13,072	0	0	0	0	86,387	-149,813	416	-63,010
Balance at 31 Dec 2012	59,126	-55,656	55,656	101,503	14,990	30,000	1,667	846,998	116,543	61,388	1,232,215

Krka Company statement of cash flows (unaudited)

EUR thousand	2013	2012
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit for the year	164,673	154,615
Adjustments for:	95,503	81,917
– amortisation/depreciation	71,466	69,612
– foreign exchange differences	2,904	-103
– investment income	-5,493	-17,515
– investment expense	1,741	5,714
– interest expense and other financial expense	1,682	2,701
– income tax	23,203	21,508
Operating profit before changes in net operating current assets	260,176	236,532
Change in trade receivables	-30,814	-34,352
Change in inventories	-413	2,746
Change in trade payables	27,425	22,946
Change in provisions	484	-1,014
Change in deferred revenue	-438	-687
Change in other current liabilities	5,786	2,893
Income taxes paid	-10,252	-21,848
Net cash from operating activities	251,954	207,216
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	3,457	1,980
Dividends received	23	17
Proportionate profit of subsidiaries	2,519	13,661
Proceeds from sale of property, plant and equipment	699	5,110
Purchase of intangible assets	-4,661	-6,340
Purchase of property, plant and equipment	-112,053	-63,620
Acquisition of subsidiaries and a share of minority interest without obtained assets	-30,952	-33,938
Refund of subsequent payments in subsidiaries	2,267	185
Non-current loans	-3,090	-25,384
Proceeds from repayment of non-current loans	1,413	3,261
Acquisition of non-current investments	-41	-89
Proceeds from sale of non-current investments	59	47
Payments/Proceeds in connection with current investments and loans	-6,162	-19,918
Payments in connection with derivative financial instruments	0	-4,987
Proceeds from derivative financial instruments	0	102
Net cash used in investing activities	-146,522	-129,913
CASH FLOWS FROM FINANCING ACTIVITIES		
Interest paid	-2,069	-3,293
Repayment of non-current borrowings	-25,500	-41,300
Non-current borrowings	1,200	800
Repayment/Acquisition of current borrowings	24,258	28,057
Dividends paid	-52,995	-49,770
Repurchase of treasury shares	-13,715	-13,072
Net cash used in financing activities	-68,821	-78,578
Net increase in cash and cash equivalents	36,611	-1,275
Cash and cash equivalents at beginning of period	13,369	15,023
Effect of exchange rate fluctuations on cash held	-563	-379
Net cash and cash equivalents at end of period	49,417	13,369